Soluble B7-H3 as a Biomarker for Osteosarcoma

Peking University People's Hospital200 enrolled

Overview

Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a biomarker for osteosarcoma treatment.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Biomarker Progression Osteosarcoma Surveillance

Interventions

ELISA: enzyme-linked immunosorbent assayDIAGNOSTIC_TEST

enzyme-linked immunosorbent assay

Eligibility

Sex: ALLMin age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * High Grade osteosarcoma verified with pathologic diagnosis. * systemic treatment-naive before the first time Blood drawing. * ECOG 0 or 1 and all the other imagings indicate that patients could tolerate standard PKUPH-OS-02 protocol neoadjuvant chemotherapy. * All radiographs are complete for clinical evaluation. Exclusion Criteria: * Patients who Can't tolerate blood drawing. * Patients without complete medical records in PKUPH system. * Patients who can't tolerate PKUPH-OS-02 neoadjuvant chemotherapy. * other conditions that investigators think are not suitable for this study.

Locations (1)

Peking University People's Hospital

Beijing, Beijing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

correlation of quantity of Protein B7-H3 Expression with clinical evaluation

Clinical evaluation according to RECIST 1.1

Time frame: 6 months

Secondary Outcomes

correlation of quantity of Protein B7-H3 Expression with histological responses

Histological responses according to Huvos Grade

Time frame: 6 months

correlation of quantity of Protein B7-H3 Expression with event-free survival

event-free survival calculated from starting systemic therapy to any tumor-related events for progression

Time frame: 2 years

correlation of quantity of Protein B7-H3 Expression with overall survival

overall survival calculated from starting systemic therapy to death

Time frame: 5 years

Central Contacts

Lu Xie, M.D.

CONTACT

+86-13401044719 xie.lu@hotmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.